Digital neurotherapeutics specialist MindMaze secures USD 105 million

MindMaze has closed a USD 105 million financing round to accelerate its global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases.

A global pioneer in the multibillion-dollar digital neurotherapeutics market, MindMaze delivers seamless digital assessments and therapeutics over the full continuum of care in over twenty countries.

Helping thousands of patients suffering from neurological conditions, MindMaze collaborates with approximately ninety healthcare providers and has a product portfolio that has received three FDA clearances and four CE marks across eight clinical indications.

The Vaud-based company has announced it has secured a USD 105 million financing was led by Concord Health Partners, AlbaCore Capital Group, and Hambro Perks. This funding will help MindMaze accelerate its global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases. 

“This funding allows us to ramp up commercial activity and expand our footprint in the U.S, as well as gain access to strategic partners as we continue to deploy solutions across the continuum of care globally,” said Tej Tadi, Founder, and CEO of MindMaze.

Founded in 2012 as an EPFL spin-off and having received the support of Hollywood actor Leonardo DiCaprio, MindMaze became the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai. The biotech currently employs 140 people, 80 of them in its Lausanne offices.